LIMN LIMN
Company Profile ↓Company Overview
LIMN (LIMN) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 104.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 30.3%.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -97.94% |
| 6 Months: | -90.19% |
| 3 Months: | -49.52% |
| 1 Month: | -19.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.91 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 104.0%.
- Healthy ROCE of 30.3%.
CONS
- Trading 97.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | -247 | -909.22K | -543.15K | -264.22K | -1.12M | -701.17K | -1.10M |
| Net Income | -1.75M | -961.21K | -601.37K | -327.53K | 113.29K | -1.82M | -1.12M |
| Diluted EPS | -2.47 | -0.05 | -0.03 | -0.02 | 0.00 | -0.07 | -0.03 |
| R&D Expense | - | 714.13K | 357.07K | - | - | - | 400.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Income | -3.33M | -2.97M |
| Net Income | -3.55M | -10.21M |
| Diluted EPS | -0.20 | -0.43 |
| R&D Expense | 2.69M | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 5.41M | 512.79K |
| Total Equity | -15.79M | -19.34M | -9.81M |
| Total Liabilities | - | 24.75M | 10.33M |
| Current Liabilities | - | 24.75M | 10.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -1.45M | -9.96M |
| Investing Cash Flow | -2.85M | -788.11K |
| Financing Cash Flow | 3.92M | 11.03M |
| Capital Expenditure | - | -13.11K |
| Free Cash Flow | - | -9.98M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 18.3% | 104.0% |
| ROCE % | 17.2% | 30.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LIMN
Liminatus Pharma, Inc. Revenue Breakdown – NASDAQ:LIMN - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5DaFVOQThFeUpkUGF3NHQzbW11TTM3WUhhdmY4NEZfNGFNUjZ2dFlyQ0ttWnI4WndoU0xtRFdYUU95bi0tRDNLRjk2Wi1VSFNwRlFiMm1VdXhscFRjVFBLS3Utb1o1VERSVEVQcnc5VzZxT0Q4Wnlv?oc=5" target="_blank">Liminat…
Samda Biolab discloses 5.1% Liminatus Pharma (LIMN) ownership position - Stock Titan
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOX2RIS1dmcGhJQ1BHdGdJVVJibGhMUGYzODR1RnNlVF9tWVh0R0J6MUluTFBuN1lVSXBZQV9IOGw0M0JUeVZWcy1NbnA3R1Vla0hQT0docFZtbGMzRWpOUGlaTmtPanFXV05vY1NJYkktR0dWR2Z3YjZkUlJPUnZaSGpGcXMybVhHNkRLY1…
Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxPeWdyd09vdXhDTFdUYXV3SG0wZGtPRmFWR1AzTW1OemRGRlhsT0VoNFNRSEdrWGJLdGNpR09XLVowWG1KdVpHalpiaXNwLWtjOTBJTFctZVBMZktOVkpWbjc2WkJpQVY5d3M4ZVhZVFdOaGtlR1R2UGliNjNaZy03VkwwSkdXalNsZU5rNz…
LIMN Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTFBSSlgzZDBSa3B6d2xfcmxraHliWlc5YzRfLXp2cU42bHZ3VXlraXFXX0EtVUFYR3NxVnJnc0NKUEtXZkd1dUp3S0VGVEhabzhkUGRvRmRnUmQ3VG1ITlE?oc=5" target="_blank">LIMN Should I Buy</a> <font c…
Liminatus Pharma, Inc. Receives Nasdaq Delisting Notice Following Non-Compliance with Market Value Requirements - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQYXdNZFdFaUhJaGhmOV9LYXhaS055ZzBXNlhPaFVjOW1uNHd6bndtM1NQX2hzSFgxem5RcE9aYVZXdzZwRll4UUtzbHYwbXVDVVJ6UkdMUnpPdjQ4QmhaY1FNLTdtUFRaRXJnWGhFT1V5MFJ6dXlkbjVaNllkQnoyUE9xUHQ3c0lKT3pQOC…
$Liminatus Pharma (LIMN.US)$ - Moomoo
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxOeF9PU09mdW1hM2hOaHRiN1NCOGZHMEpJS2NjV3VzNW9oMUpkckdrRnFqTjc3bXI2TTQ0LTBtZzJMeUtHckhKLS1ZcFU5RHJqMGJTRzAxZllwa2d2LWNRQWVUdjNSbmtOREpuVzVOODNVcTNnZDcyWnNRMGNXcE85eC14Y0g?oc=5" targ…
LIMN — Frequently Asked Questions
What is the current share price of LIMN?
As of 2026-08-05 17:25 PDT, LIMN trades at $0.10 on NASDAQ/NYSE. Its 52-week range is $0.10 to $5.09.
What is the P/E ratio of LIMN?
LIMN trades at a trailing price-to-earnings (P/E) ratio of -0.23.
What is the return on equity (ROE) of LIMN?
LIMN has a return on equity (ROE) of 103.99%. Its return on capital employed (ROCE) is 30.33%.
Is LIMN a good stock to buy?
This page provides a data-driven analysis of LIMN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.